The peptide is stable in stomach acid, making oral delivery viable
The "minimal initial benefit" group (approximately 5-10% of users) reported limited improvements during treatment making discontinuation effects irrelevant, typically explained by inadequate product quality with degraded or low-concentration GHK-Cu, inappropriate application technique reducing absorption, unrealistic expectations exceeding what any topical can achieve, severe underlying pathology requiring medical intervention beyond cosmetic peptides, or individual non-responsiveness to copper peptide treatment for genetic or physiological reasons
This product is designated FOR RESEARCH USE ONLY (RUO)
This common preservative booster has a stronger affinity for copper than the peptide does
Growth hormone receptor upregulation: Animal studies suggest BPC-157 increases growth hormone receptor expression in tendon tissue, potentially amplifying endogenous GH signaling locally rather than elevating circulating GH
Shipping is free for orders of 250 or more